Our analysis in another randomly selected dataset (the exploration dataset; containing 60% of samples from the total dataset) showed that the survival probabilities of these patients could be dramatically improved when PIK3CA + HMCN1 mutations were also found with LRP1B and AHNAK2 mutations in STAD patients (Fig. 3b-c). This evidence concerns the gene HMCN1 and gastric adenocarcinoma.